{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/palliative-care-malignant-skin-ulcer/how-up-to-date-is-this-topic/update/","result":{"pageContext":{"chapter":{"id":"ee67bddb-c899-5cdf-8bd4-b6ce53a64863","slug":"update","fullItemName":"Update","depth":2,"htmlHeader":"<!-- begin field 1b92ae9f-476b-42c6-86c1-f6151ea716eb --><h2>Update</h2><!-- end field 1b92ae9f-476b-42c6-86c1-f6151ea716eb -->","summary":null,"htmlStringContent":"<!-- begin item e259c271-8cfe-4b58-a6bb-e5fe650c460b --><!-- end item e259c271-8cfe-4b58-a6bb-e5fe650c460b -->","topic":{"id":"a66236f8-759a-578d-b8e0-d9b9f4d4b17b","topicId":"594ae15d-e8a6-49e1-9bc4-b8235684b211","topicName":"Palliative care - malignant skin ulcer","slug":"palliative-care-malignant-skin-ulcer","lastRevised":"Last revised in October 2018","chapters":[{"id":"8aae23f3-652c-5220-96a9-570f5c6a4197","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"3fae4ef2-1de8-537a-8d87-bb0f0e925ca2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7cd1b72b-f0ca-5fa9-a739-760c7315a4c6","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"28f3598f-1a0b-5fa6-885c-7908290eef3d","slug":"changes","fullItemName":"Changes"},{"id":"ee67bddb-c899-5cdf-8bd4-b6ce53a64863","slug":"update","fullItemName":"Update"}]},{"id":"7209a66f-e985-5a26-b178-2d841634478d","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"a512b109-ae33-58f1-9b3e-1bb25ba17ed1","slug":"goals","fullItemName":"Goals"},{"id":"d4f96da2-1dfd-5b18-aeec-d33fe0b56967","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ec220b93-2051-5b93-ada7-66029759c688","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e8a03776-8e6f-57f0-9d78-72e639758d72","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a89f6107-4d65-56f2-a108-583acc3aa1dd","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"99d9f654-11a9-5749-882a-6bfac0a995ad","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"ba712e36-e31f-53bb-9746-10f4bb36e7e9","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8ae192ef-3ead-55f6-b5dc-e15c6fbe8e92","slug":"definition","fullItemName":"Definition"},{"id":"6045e3e4-960f-5f2a-949e-66eaa7d7fd27","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"fb13b65f-08f4-5ac4-b21a-bbba9bec2bce","slug":"complications","fullItemName":"Complications"}]},{"id":"5750038d-2dca-5b1b-9cef-5ec97727cd6c","fullItemName":"Management","slug":"management","subChapters":[{"id":"576c0eda-301a-5d5f-9d9f-34505854cac8","slug":"palliative-cancer-care-malignant-skin-ulcer","fullItemName":"Scenario: Palliative cancer care - malignant skin ulcer"},{"id":"4c917ea3-8a66-5e50-9cd2-a4494533a824","slug":"end-of-life-care","fullItemName":"Scenario: End of life care"}]},{"id":"c6fd3a21-3f33-5f10-9f9b-22da77001d52","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"cce56ef7-baec-5a1f-9927-a88b697e0b79","slug":"metronidazole","fullItemName":"Metronidazole"}]},{"id":"6fb5a8ca-5e8b-5cea-9647-c8d15aa9fd31","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"c16178c4-497b-57f0-8903-94f79dc3e888","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"0676abc6-76ab-5fcf-816a-0f0fd3c08737","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"7c58ec18-ffff-5082-9660-ff776be47414","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"ec9b77b3-9f46-5d3d-89fe-1d2ba54e8e03","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"2b921fab-b857-5da1-90cd-616aa087e15a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"f5f487fa-4ace-58e9-aefa-a01924f86557","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"0a5cfba7-db2d-58b1-b705-aef0029b384e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"7cd1b72b-f0ca-5fa9-a739-760c7315a4c6","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"5764e13c-8a3f-5679-ba01-e0d1a236102c","slug":"new-evidence","fullItemName":"New evidence","depth":3,"htmlHeader":"<!-- begin field 16ead5ed-46d0-4031-ad7d-4c766df88a21 --><h3>New evidence</h3><!-- end field 16ead5ed-46d0-4031-ad7d-4c766df88a21 -->","summary":null,"htmlStringContent":"<!-- begin item 968c08b9-5a81-40e4-a2e7-8f1324716500 --><!-- begin field 86f5b31c-a7e9-4a95-8965-8b902e1f37c7 --><h3>Evidence-based guidelines</h3><!-- end field 86f5b31c-a7e9-4a95-8965-8b902e1f37c7 --><!-- begin field 0de11ec6-02f5-4a02-8cca-0a90dc689c38 --><p>No new evidence-based guidelines since 1 October 2016.</p><!-- end field 0de11ec6-02f5-4a02-8cca-0a90dc689c38 --><!-- begin field 1eb871eb-7bfd-4c59-9e20-8973073f3e76 --><h3>HTAs (Health Technology Assessments)</h3><!-- end field 1eb871eb-7bfd-4c59-9e20-8973073f3e76 --><!-- begin field 6019e089-f997-4297-bae8-1c7e90fd113a --><p>No new HTAs since 1 October 2016.</p><!-- end field 6019e089-f997-4297-bae8-1c7e90fd113a --><!-- begin field 6d21ddcd-c7f7-4960-b950-f716d469332d --><h3>Economic appraisals</h3><!-- end field 6d21ddcd-c7f7-4960-b950-f716d469332d --><!-- begin field 7d95a592-0673-47fe-83f4-8fc8d83dec09 --><p>No new economic appraisals relevant to England since 1 October 2016.</p><!-- end field 7d95a592-0673-47fe-83f4-8fc8d83dec09 --><!-- begin field 963925ef-5959-4b36-99d8-09acc9a352ed --><h3>Systematic reviews and meta-analyses</h3><!-- end field 963925ef-5959-4b36-99d8-09acc9a352ed --><!-- begin field 47608385-235d-48ab-9c78-10f044e28464 --><p>No new systematic reviews published since 1 October 2016.</p><!-- end field 47608385-235d-48ab-9c78-10f044e28464 --><!-- begin field f38bb3eb-46e0-478e-aca8-969dc4e47cb3 --><h3>Primary evidence</h3><!-- end field f38bb3eb-46e0-478e-aca8-969dc4e47cb3 --><!-- begin field 8d6687cb-bd19-4ecb-aa64-3cf1e4819ba6 --><p>No new randomized controlled trials published in the major journals since 1 October 2016.</p><!-- end field 8d6687cb-bd19-4ecb-aa64-3cf1e4819ba6 --><!-- end item 968c08b9-5a81-40e4-a2e7-8f1324716500 -->","subChapters":[]},{"id":"fa7ac415-7cd5-5b4f-9e4f-938383af83fd","slug":"new-policies","fullItemName":"New policies","depth":3,"htmlHeader":"<!-- begin field 3b6cb791-afb9-4759-85d5-87f3c0041888 --><h3>New policies</h3><!-- end field 3b6cb791-afb9-4759-85d5-87f3c0041888 -->","summary":null,"htmlStringContent":"<!-- begin item b46489a7-4e23-4482-b44f-fa1043ef766a --><!-- begin field bb888e57-e280-4e29-9c39-b2b41b010661 --><p>No new national policies or guidelines since 1 October 2016.</p><!-- end field bb888e57-e280-4e29-9c39-b2b41b010661 --><!-- end item b46489a7-4e23-4482-b44f-fa1043ef766a -->","subChapters":[]},{"id":"0df26840-ac21-5a0d-8248-3a75da041b55","slug":"new-safety-alerts","fullItemName":"New safety alerts","depth":3,"htmlHeader":"<!-- begin field 164e5c4c-3c0c-4cd2-998b-c58cc173a4e2 --><h3>New safety alerts</h3><!-- end field 164e5c4c-3c0c-4cd2-998b-c58cc173a4e2 -->","summary":null,"htmlStringContent":"<!-- begin item be614b34-1bda-4cc8-a941-eef833d73387 --><!-- begin field eb94de86-67e6-4984-8bf5-48b7c6f22157 --><p>No new safety alerts since 1 October 2016.</p><!-- end field eb94de86-67e6-4984-8bf5-48b7c6f22157 --><!-- end item be614b34-1bda-4cc8-a941-eef833d73387 -->","subChapters":[]},{"id":"6a3d61dd-b118-51f5-b0bc-1ed278367c72","slug":"changes-in-product-availability","fullItemName":"Changes in product availability","depth":3,"htmlHeader":"<!-- begin field 95885fc8-f08e-4d98-922c-5b6a25b399b8 --><h3>Changes in product availability</h3><!-- end field 95885fc8-f08e-4d98-922c-5b6a25b399b8 -->","summary":null,"htmlStringContent":"<!-- begin item f198f691-fd5e-4c0b-8484-79514cf05c41 --><!-- begin field 8fe13987-0d00-4674-b822-364bba245b3c --><ul><li>Guidance states evidence supports adoption of UrgoStart dressings in NHS as option for people with diabetic foot-or venous leg ulcers after any modifiable factors such as infection have been treated because they are linked to increased wound healing vs. non-interactive dressings. For more information, see <a href=\"https://www.nice.org.uk/guidance/mtg42\" data-hyperlink-id=\"23e7d2a3-ce13-4fb1-bfe6-a9fc00b92241\">here</a>. </li></ul><!-- end field 8fe13987-0d00-4674-b822-364bba245b3c --><!-- end item f198f691-fd5e-4c0b-8484-79514cf05c41 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}